115 related articles for article (PubMed ID: 34019887)
1. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
2. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH
Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159
[TBL] [Abstract][Full Text] [Related]
3. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers.
Okoye EI; Bruegl AS; Fellman B; Luthra R; Broaddus RR
Int J Gynecol Pathol; 2016 Jan; 35(1):8-15. PubMed ID: 25851713
[TBL] [Abstract][Full Text] [Related]
4. Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.
Yang S; Jia Y; Liu X; Winters C; Wang X; Zhang Y; Devor EJ; Hovey AM; Reyes HD; Xiao X; Xu Y; Dai D; Meng X; Thiel KW; Domann FE; Leslie KK
Oncotarget; 2014 Oct; 5(20):9783-97. PubMed ID: 25229191
[TBL] [Abstract][Full Text] [Related]
5. Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases.
Wei JJ; Paintal A; Keh P
Arch Pathol Lab Med; 2013 Nov; 137(11):1574-83. PubMed ID: 24168495
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
Devor EJ; Miecznikowski J; Schickling BM; Gonzalez-Bosquet J; Lankes HA; Thaker P; Argenta PA; Pearl ML; Zweizig SL; Mannel RS; Brown A; Ramirez NC; Ioffe OB; Park KJ; Creasman WT; Birrer MJ; Mutch D; Leslie KK
Gynecol Oncol; 2017 Dec; 147(3):648-653. PubMed ID: 28969912
[TBL] [Abstract][Full Text] [Related]
8. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.
Hu Z; Wu Z; Liu W; Ning Y; Liu J; Ding W; Fan J; Cai S; Li Q; Li W; Yang X; Dou Y; Wang W; Peng W; Lu F; Zhuang X; Qin T; Kang X; Feng C; Xu Z; Lv Q; Wang Q; Wang C; Wang X; Wang Z; Wang J; Jiang J; Wang B; Mills GB; Ma D; Gao Q; Li K; Chen G; Chen X; Sun C
Nat Genet; 2024 Apr; 56(4):637-651. PubMed ID: 38565644
[TBL] [Abstract][Full Text] [Related]
9. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
Ring KL; Yates MS; Schmandt R; Onstad M; Zhang Q; Celestino J; Kwan SY; Lu KH
Int J Gynecol Cancer; 2017 Jun; 27(5):854-862. PubMed ID: 28498246
[TBL] [Abstract][Full Text] [Related]
10. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Iyer RB; Malpica AL; Kavanagh JJ; Bodurka DC; Schmeler K; Deavers M
Gynecol Oncol; 2012 Jun; 125(3):661-6. PubMed ID: 22406638
[TBL] [Abstract][Full Text] [Related]
11. Identification of a gene expression signature for survival prediction in type I endometrial carcinoma.
Levan K; Partheen K; Osterberg L; Olsson B; Delle U; Eklind S; Horvath G
Gene Expr; 2010; 14(6):361-70. PubMed ID: 20635577
[TBL] [Abstract][Full Text] [Related]
12. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
Soliman PT; Westin SN; Iglesias DA; Fellman BM; Yuan Y; Zhang Q; Yates MS; Broaddus RR; Slomovitz BM; Lu KH; Coleman RL
Clin Cancer Res; 2020 Feb; 26(3):581-587. PubMed ID: 31628143
[TBL] [Abstract][Full Text] [Related]
13. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
Lindemann K; Malander S; Christensen RD; Mirza MR; Kristensen GB; Aavall-Lundqvist E; Vergote I; Rosenberg P; Boman K; Nordstrøm B
BMC Cancer; 2014 Feb; 14():68. PubMed ID: 24498853
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
Cottu PH; Bonneterre J; Varga A; Campone M; Leary A; Floquet A; Berton-Rigaud D; Sablin MP; Lesoin A; Rezai K; Lokiec FM; Lhomme C; Bosq J; Bexon AS; Gilles EM; Proniuk S; Dieras V; Jackson DM; Zukiwski A; Italiano A
PLoS One; 2018; 13(10):e0204973. PubMed ID: 30304013
[TBL] [Abstract][Full Text] [Related]
16. The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence.
Buchynska L; Gordiienko I; Glushchenko N; Iurchenko N
PLoS One; 2024; 19(4):e0302075. PubMed ID: 38669256
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of transcription factor
Onoprienko A; Hofstetter G; Muellauer L; Dorittke T; Polterauer S; Grimm C; Bartl T
Int J Gynecol Cancer; 2024 Jun; 34(6):840-846. PubMed ID: 38508586
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma.
Dai M; Zhu XL; Liu F; Xu QY; Ge QL; Jiang SH; Yang XM; Li J; Wang YH; Wu QK; Ai ZH; Teng YC; Zhang ZG
Sci Rep; 2017 Jan; 7():41404. PubMed ID: 28112250
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of RHCG in endometrial cancer.
Wang H; Jin H; Zhao S
Histol Histopathol; 2024 May; 39(5):611-621. PubMed ID: 37732703
[TBL] [Abstract][Full Text] [Related]
20. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer.
Merritt MA; Strickler HD; Hutson AD; Einstein MH; Rohan TE; Xue X; Sherman ME; Brinton LA; Yu H; Miller DS; Ramirez NC; Lankes HA; Birrer MJ; Huang GS; Gunter MJ
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):719-726. PubMed ID: 33622671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
